HIF1A and cancer: lncRNA-HISLA combines with prolyl hydroxylase domain 2 which targets HIF-1α to repress its hydroxylation and degradation, enhancing aerobic glycolysis and apoptosis resistance of BC cells. Meanwhile, BC cells can release lactate to increase the expression of HISLA in TAM, forming a synergistic closed loop between TAMs and cancer cells.